Briefly summarized, embodiments of the present invention are directed to a low-profile access port for subcutaneous implantation within the body of a patient. The access port includes a receiving cup that provides a relatively large subcutaneous target to enable a catheter-bearing needle to access the port without difficulty. In addition, the access port includes a valve/seal assembly to permit pressurized fluid injection through the port while preventing backflow.
In one embodiment, therefore, a low-profile access port comprises a body including a conduit with an inlet port at a proximal end thereof, and a receiving cup. The receiving cup is concavely shaped to direct a catheter-bearing needle into the conduit via the inlet port. The receiving cup is oriented substantially toward a skin surface when subcutaneously implanted within the patient to ease needle impingement thereon. A valve/seal assembly disposed in the conduit enables passage of the catheter therethrough while preventing fluid backflow.
In another embodiment, a low-profile access port for subcutaneous implantation within the patient is disclosed and comprises a body including a conduit with an inlet port at a proximal end thereof, and a receiving cup. The receiving cup is funnel shaped to direct a catheter-bearing needle into the conduit via the inlet port. The conduit is defined by the body and extends from the inlet port to an outlet defined by a stem. A bend in the conduit enables catheter advancement past the bend while preventing needle advancement. A valve/seal assembly is also disposed in the conduit and enables passage of the catheter therethrough while preventing fluid backflow. The body includes radiopaque indicia configured to enable identification of the access port via x-ray imaging.
In light of the above, embodiments herein are generally directed to a vascular access device, also referred to herein as an access port, for subcutaneous implantation within the body of a patient. The implanted access port is transcutaneously accessible by a catheter-bearing needle, such as a peripheral intravenous (“PIV”) catheter, so as to place the PIV catheter into fluid communication with the access port. A fluid outlet of the access port is operably connected to an in-dwelling catheter disposed within the vasculature of a patient, in one embodiment, to enable the infusion into and/or removal of fluids from the patient's vasculature to take place via the PIV catheter.
These and other features of embodiments of the present invention will become more fully apparent from the following description and appended claims, or may be learned by the practice of embodiments of the invention as set forth hereinafter.
A more particular description of the present disclosure will be rendered by reference to specific embodiments thereof that are illustrated in the appended drawings. It is appreciated that these drawings depict only typical embodiments of the invention and are therefore not to be considered limiting of its scope. Example embodiments of the invention will be described and explained with additional specificity and detail through the use of the accompanying drawings in which:
Reference will now be made to figures wherein like structures will be provided with like reference designations. It is understood that the drawings are diagrammatic and schematic representations of exemplary embodiments of the present invention, and are neither limiting nor necessarily drawn to scale.
For clarity it is to be understood that the word “proximal” refers to a direction relatively closer to a clinician using the device to be described herein, while the word “distal” refers to a direction relatively further from the clinician. For example, the end of a catheter placed within the body of a patient is considered a distal end of the catheter, while the catheter end remaining outside the body is a proximal end of the catheter. Also, the words “including,” “has,” and “having,” as used herein, including the claims, shall have the same meaning as the word “comprising.”
Embodiments of the present invention are generally directed to an access port for subcutaneous implantation within the body of a patient. The implanted access port is transcutaneously accessible by a catheter-bearing needle, such as a peripheral intravenous (“PIV”) catheter, so as to place the PIV catheter into fluid communication with the access port. A fluid outlet of the access port is operably connected to an in-dwelling catheter disposed within the vasculature of a patient, in one embodiment, to enable the infusion into and/or removal of fluids from the patient's vasculature to take place via the PIV catheter.
In accordance with one embodiment, the access port defines a low profile so as to facilitate ease of placement within the subcutaneous tissue of the patient. Further, the access port is configured to provide a relatively large subcutaneous target to enable the PIV catheter or other suitable catheter-bearing needle to access the port without difficulty. In addition, the access port includes a valve/seal assembly to permit the injection of fluids through the access port at a relatively high flow rate, such as about 5 ml per second at a pressure of about 300 psi (also referred to herein as “power injection”). Possible applications for the access port described herein include administration of medicaments and other fluids to the patient, pheresis/apheresis, fluid aspiration, etc.
Reference is first made to made to
The port body 12 defines in the present embodiment a substantially concavely-shaped receiving cup 14 for receiving and directing a catheter-bearing needle (
Palpation features 26 are included with the port body 12 to assist a clinician to locate and/or identify the port 10 via finger palpation after implantation under the skin of the patient. In detail, the palpation features 26 in the present embodiment include a bump 26A disposed near the proximal end of the receiving cup 14 and a ridge 26B disposed above and curving around a distal portion of the receiving cup.
A guide groove 28 is defined on the receiving cup 14 and is longitudinally aligned with the inlet port 16 of the conduit 18. The guide groove 28 is defined as a depression with respect to adjacent portions of the surface of the receiving cup 14 and extends distally along the receiving cup surface from a proximal portion of the receiving cup so as to provide a guide path to guide the distal tip of the catheter-bearing needle toward the inlet port 16 once impingement of the needle into the guide groove is made. This in turn reduces the chance the needle will slide across and off the receiving cup 14 during insertion. Note that these and other similar features, though differing in shape and configuration, can also be included on the other ports disclosed herein.
As best seen in
The conduit 18 then extends to and through a cavity 20A defined by a valve housing 20 of the port body. The conduit 18 extends to a distal open end of the stem 24 of the port 10. The conduit 18 is sized so as to enable the catheter 40 (
As mentioned, the valve housing 20 defines a cavity 20A through which the conduit passes and which houses a valve/seal assembly 22. The valve/seal assembly 22 includes a sealing element, or seal 32, which defines a central hole through which the catheter 40 can pass, a first slit valve 34A and a second slit valve 34B. The seal 32 and valves 34A, 34B are sandwiched together in one embodiment and secured in place within the cavity 20A as shown in
The seal 32 and valves 34A, 34B of the valve/seal assembly 22 cooperate to enable fluid-tight passage therethrough of the catheter 40 (
The port 10 in the present embodiment includes an overmolded portion 36 that covers the port body 12. The overmolded portion 36 includes silicone or other suitably compliant material and surrounds the body 12 as shown so as to provide a relatively soft surface for the port 10 and reduce patient discomfort after port implantation. The overmolded portion 36 includes two predetermined suture locations 38, best seen in
The needle 42 is manipulated until the distal tip 42A is received into the guide groove 28, which will enable the distal tip to be guided along the groove to the inlet port 16. The needle 42 is then inserted through the inlet port 16 and into the first portion 18A of the conduit 18 until it is stopped by the bend 30. The needle 42 can then be proximally backed out a small distance, and the catheter 40 advanced over the needle such that the catheter bends and advances past the bend 30 into the second portion 18B of the conduit 18. Catheter advancement continues such that a distal end 40A of the catheter 40 advances into and past the hole of the seal 32 and through both slits of the slit valves 34A, 34B of the valve/seal assembly 40. Once the distal end 40A of the catheter 40 has extended distally past the valve/seal assembly 22, further advancement can cease and fluid transfer through the catheter 40 and port 10 can commence, including infusion and/or aspiration through the stem 24. Once fluid transfer is completed, the catheter 40 can be withdrawn proximally through the valve/seal assembly 22 and the conduit, then withdrawn through the surface 44 of the skin and out of the patient.
A valve/seal assembly 122 is disposed within a cavity 120A that is defined by a valve housing 120, which in the present embodiment, is defined by the first body portion 112A. The valve/seal assembly 122 includes a proximal seal 132 with a central hole for catheter passage, two slit valves 134A, 134B each with a slit arranged at a 90-degree offset with respect to the other, and a distal seal 135 with a central hole, also referred to herein as a sphincter seal.
The distal seal 135 includes on its distal surface a frustoconical portion 135A disposed about the seal central hole that is configured to provide a sphincter-like seal about the outer surface of a catheter when it extends through the valve/seal assembly. The frustoconical portion 135A is disposed such that any back-flowing fluid impinging on the frustoconical portion will cause the seal to secure itself about the outer surface of the catheter in an even tighter engagement, thus preventing backflow past the catheter outer surface when high fluid pressures are present, such as in the case of power injection. As mentioned, other valve/seal combinations can also be included in the valve/seal assembly.
In the present embodiment, the receiving cup 114 and portion of the conduit 118 proximal to the valve/seal assembly 122 both include a needle-impenetrable lining that prevents the distal end of a needle from gouging the surface when impinging thereon. This, in turn, prevents the undesirable creation of material flecks dug by the needle. Various suitable materials can be employed for the needle-impenetrable material, including glass, ceramic, metals, etc. In one embodiment, the components of the port 110 are all non-metallic such that the port is considered MRI-safe, by which the port does not produce undesired artifacts in MRI images taken of the patient when the port is in implanted therewithin.
In the present embodiment, the CT radiopaque indicia 128 indicate to an observer that the port is capable of power injection of fluids therethrough. In addition to this characteristic, other characteristics can be indicated by various other types of indicia as appreciated by one skilled in the art.
Further, in the present embodiment the top view of the port 110 of
Reference is now made to
In accordance with one embodiment, the access port defines a relatively low profile so as to facilitate ease of placement within the subcutaneous tissue of the patient. Further, the access port is configured to provide a relatively large subcutaneous target to enable the PIV catheter or other suitable catheter-bearing needle to access the port without difficulty. In addition, the access port includes a valve/seal assembly to permit power injection of fluids through the access port. As before, possible applications for the access port described herein include administration of medicaments and other fluids to the patient, pheresis/apheresis, fluid aspiration, etc.
Reference is first made to
The port body first portion 512A defines in the present embodiment a substantially funnel-shaped receiving cup 514 for receiving and directing a catheter-bearing needle (
Together with
The conduit 518 then extends to and through a cavity 520A defined by a valve housing 520 of the port body 12 where a third conduit portion 518C extends to a distal open end of the stem 524 of the port 510. In the present embodiment the conduit 518 is sized so as to enable the catheter 40 (
As mentioned, the valve housing 520, defined by portions of the first and second portions 512A, 512B of the body 512 defines a cavity 520A through which the conduit 518 passes and which houses a valve/seal assembly 522. The valve/seal assembly 522 includes a sealing element, or seal 532, which defines a central hole 532A (
The seal 532 and valve 534 of the valve/seal assembly 522 cooperate to enable fluid-tight passage therethrough of the catheter 40 (
The port 510 in the present embodiment includes an overmolded portion 536 that covers a majority portion of the port body 512. The overmolded portion 536 includes silicone, such as SILASTIC® Q7-4850 liquid silicone rubber or other suitably compliant material and surrounds the body 512 as shown so as to provide a relatively soft surface for the port 510 and reduce patient discomfort after port implantation within the patient body. The overmolded portion 536 includes in one embodiment predetermined suture locations 538, best seen in
The needle 42 is manipulated by the clinician and guided by impingement on the receiving cup 514 until the needle distal tip 42B is guided to the inlet port 516. The needle 42 is then inserted through the inlet port 516 and into the first portion 518A of the conduit 518 until it is stopped by the bend 530, as seen in
Once the distal end 40B of the catheter 40 has extended distally past the valve/seal assembly 522, further advancement is prevented by impingement of the catheter distal end against an annular stop surface 539 included in the third conduit portion 518C defined by the stem 524, as shown in
Once the catheter 40 is positioned as shown in
In another embodiment the radiopaque indicia 528 can be included by employing radiopaque material that can be formed as an insert that is insert-molded included in the port body, such as an initially flowable material that is injected into a cavity of the port body before hardening, etc. In embodiments where the port body is metallic, the radiopaque indicia can be formed by metal injection molding, machining, etching, engraving, or otherwise producing a relative thickness difference between the indicia and the surrounding port body material so as to produce an x-ray-discernible contrast that shows up in an x-ray image, similar to
In addition to above designation, other characteristics can be indicated by various other types of radiopaque indicia as appreciated by one skilled in the art.
As in other embodiments described herein, in one embodiment the perimeter of the receiving cup (or other suitable location) can include palpation features, such as three raised bumps in the overmolded portion 536 to assist in locating the position of the receiving cup 514 post-implantation when they are palpated by a clinician prior to needle insertion into the patient. Various other palpation features could be included with the port, in other embodiments, including disposal on the receiving cup itself, etc.
Reference is now made to
Both port body first portions 812A define in the present embodiment a substantially funnel-shaped receiving cup 814 for receiving and directing the catheter-bearing needle 42 (
Note that, as already mentioned, palpation features can be included with the port body 812 in one embodiment to assist a clinician to locate and/or identify the port 810 via finger palpation after implantation under the skin of the patient. Note that a variety of sizes, configurations, numbers, etc., of palpation features can be included on the port. In another embodiment, a guide groove can be defined on the receiving cup 814 to be longitudinally aligned with the inlet port 816 of the conduit 818, as discussed in connection with the embodiment of
As best seen in
The second conduit portion 818B of each port body first portion 812A distally extends to a cavity 820A defined by the press-fit junction of the port body first portion and the second portion 812B, as seen in
As mentioned, the cavities 820A, each defined by the junction of the respective first portion 812A and the second portion 812B of the port body 812, each define a space through which the conduit 818 passes and in which is housed a valve/seal assembly 822. In the present embodiment and as best seen in
As mentioned, the slits 834A of the slit valve 834 are orthogonally offset from one another by about 90 degrees in the present embodiment, though other relationships are possible, including the use of two single-slit valves sandwiched together with one another. Note that in the present embodiment the slit valve 834 includes a central depression (as in previous embodiments, such as is shown in
As with previous embodiments, the seal 832 and slit valve 834 of the valve/seal assembly 822 cooperate to enable fluid-tight passage therethrough of the catheter 40 (see, e.g.,
The port 810 in the present embodiment includes an overmolded portion 836 that covers a portion of the port body 812, including a majority portion of each of the two first portions 818A. The overmolded portion 836 includes silicone, such as SILASTIC® Q7-4850 liquid silicone rubber or other suitably compliant material and surrounds the portions of the body 812 as shown in
In one embodiment, it is appreciated that the receiving cups 814 can be oriented in other configurations.
Reference is now made to
The port body first portion 612A defines in the present embodiment two substantially funnel-shaped receiving cups 614 for receiving and directing the catheter-bearing needle 42 (
In particular, the substantially funneled-shape of each receiving cup 614 is configured to direct the catheter-bearing needle 42 impinging thereon toward an inlet port 616 that serves as an opening for a respective one of two conduits 618 defined by the port body 612, one conduit for each receiving cup. The open and shallow nature of each receiving cup 614, angled toward the skin surface of the patient enables the receiving cup to present a large, easily accessible target for the needle when introduced into the skin and directed toward the subcutaneously implanted access port 610.
The port body 612 further defines a palpation feature 637, here configured as a raised surface interposed between the longitudinally aligned receiving cups 614. As mentioned above, the palpation feature 637 is included with the port body 612 to assist a clinician to locate and/or identify the port 610 via finger palpation after implantation under the skin of the patient. Note that a variety of sizes, configurations, numbers, etc., of palpation features can be included on the port. In another embodiment, a guide groove can be defined on each receiving cup 614 to be longitudinally aligned with the inlet port 616 of the conduit 618, as in previous embodiments.
As best seen in
The first portion 618A of the relatively more distal of the two receiving cups 614 extends to a cavity 620A defined by and proximate to the distal portion of the first portion 612A of the port body 612, as best seen in
The conduit 618 for the relatively more distal receiving cup 614 extends from the cavity 620A to a third conduit portion 618C defined by the second portion 612A of the port body 612, as seen in
As mentioned, the cavities 620A, each disposed in the fluid pathway defined by the various portions of the conduits 618, each define a space through which the conduit 618 passes and in which is housed a valve/seal assembly 622. In the present embodiment and as best seen in
In the present embodiment, the seal 632 and valves 634 are composed of silicone, such as SILASTIC® Q7-4850 liquid silicone rubber available from Dow Corning Corporation, though other suitably compliant materials can be employed. In one embodiment, silicone oil, such as NuSil Technology Med 400 silicone oil, is included with the seal 632 and valves 634 to enhance lubricity and extend component life. In another embodiment, the silicone oil is infused into the silicone. Also, and as has been mentioned with other embodiments, other seal/valve configurations can also be employed in the port 610.
Reference is now made to
The port body first portion 712A defines in the present embodiment two substantially concavely-shaped receiving cups 714, side-by-side in a spaced-apart arrangement, for receiving and directing the catheter-bearing needle 42 (
The open and shallow nature of each receiving cup 714, angled toward the skin surface of the patient enables the receiving cup to present a large, easily accessible target for the needle when introduced into the skin and directed toward the subcutaneously implanted access port 710.
The port body 712 includes a plurality of palpation features 737, here implemented as ridges extending distally from the receiving cups 714, to assist a clinician to locate and/or identify the port 710 via finger palpation after implantation under the skin of the patient. Note that a variety of sizes, configurations, numbers, etc., of palpation features can be included on the port.
As best seen in
As mentioned, the cavities, each defined by the junction of the respective first portion 712A and the second portion 712B of the port body 712, each define a space through which the conduit 718 passes and in which is housed the valve/seal assembly 722. In the present embodiment and as best seen in
As mentioned, the slits of the slit valves 734 are orthogonally offset from one another by about 90 degrees in the present embodiment, though other relationships are possible, including the use of a single slit valve including two orthogonal slits. These and other modifications to this and the other valve/seal assembly embodiments herein are therefore contemplated.
As with previous embodiments, the seal 732 and slit valves 734 of the valve/seal assembly 722 cooperate to enable fluid-tight passage therethrough of the catheter 40 (see, e.g.,
Though not explicitly shown here, the port 710, as with other embodiments herein, can include radiopaque indicia configured to enable the port to be radiographically identified after implantation into the patient body. In one embodiment, the indicia include the letters “IV” and “CT” to indicate suitability of the port 710 to receive peripheral IV catheters and that the port is capable of power injection of fluids therethrough. Of course, a variety of other indicia, including letters, numbers, symbols, etc., may be used.
Though single and dual-port configurations have been described herein, it is appreciated that ports including more than two receiving cups are contemplated. Note also that certain of the receiving cups described herein are described as funnel shaped, while other receiving cups are described herein as concavely shaped. It is noted that that the receiving cups can interchangeably include aspects of one or the other, or both, of these receiving cup shapes, according to a particular embodiment.
In
Embodiments of the invention may be embodied in other specific forms without departing from the spirit of the present disclosure. The described embodiments are to be considered in all respects only as illustrative, not restrictive. The scope of the embodiments is, therefore, indicated by the appended claims rather than by the foregoing description. All changes that come within the meaning and range of equivalency of the claims are to be embraced within their scope.
This application is a continuation-in-part of U.S. patent application Ser. No. 14/162,113, filed Jan. 23, 2014, and titled “Low-Profile Access Port,” which claims the benefit of U.S. Provisional Application No. 61/755,913, filed Jan. 23, 2013, and titled “Low Profile Access Port.” This application also claims the benefit of the following: U.S. Provisional Application No. 62/421,131, filed Nov. 11, 2016, and titled “Low-Profile Vascular Access Device; and U.S. Provisional Application No. 62/552,681, filed Aug. 31, 2017, and titled “Low-Profile Single and Dual Vascular Access Device.” Each of the aforementioned applications is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3951147 | Tucker et al. | Apr 1976 | A |
4184489 | Burd | Jan 1980 | A |
4222374 | Sampson et al. | Sep 1980 | A |
4400169 | Stephen | Aug 1983 | A |
4447237 | Frisch et al. | May 1984 | A |
4496349 | Cosentino | Jan 1985 | A |
4543088 | Bootman et al. | Sep 1985 | A |
4559039 | Ash et al. | Dec 1985 | A |
4569675 | Prosl et al. | Feb 1986 | A |
4673394 | Fenton, Jr. et al. | Jun 1987 | A |
4692146 | Hilger | Sep 1987 | A |
4695273 | Brown | Sep 1987 | A |
4704103 | Stober et al. | Nov 1987 | A |
4710174 | Moden et al. | Dec 1987 | A |
4762517 | McIntyre et al. | Aug 1988 | A |
4767410 | Moden et al. | Aug 1988 | A |
4772270 | Wiita et al. | Sep 1988 | A |
4772276 | Wiita et al. | Sep 1988 | A |
4778452 | Moden et al. | Oct 1988 | A |
4790826 | Elftman | Dec 1988 | A |
4802885 | Weeks et al. | Feb 1989 | A |
4804054 | Howson et al. | Feb 1989 | A |
4820273 | Reinicke | Apr 1989 | A |
4861341 | Woodburn | Aug 1989 | A |
4886501 | Johnston et al. | Dec 1989 | A |
4892518 | Cupp | Jan 1990 | A |
4897081 | Poirier et al. | Jan 1990 | A |
4904241 | Bark | Feb 1990 | A |
4915690 | Cone et al. | Apr 1990 | A |
4929236 | Sampson | May 1990 | A |
4963133 | Whipple | Oct 1990 | A |
4978338 | Melsky et al. | Dec 1990 | A |
5013298 | Moden et al. | May 1991 | A |
5041098 | Loiterman et al. | Aug 1991 | A |
5045060 | Melsky et al. | Sep 1991 | A |
5045064 | Idriss | Sep 1991 | A |
5053013 | Ensminger et al. | Oct 1991 | A |
5057084 | Ensminger | Oct 1991 | A |
5084015 | Moriuchi | Jan 1992 | A |
5090954 | Geary | Feb 1992 | A |
5108377 | Cone et al. | Apr 1992 | A |
5137529 | Watson et al. | Aug 1992 | A |
5147321 | Slonina | Sep 1992 | A |
5147483 | Melsky et al. | Sep 1992 | A |
5158547 | Doan et al. | Oct 1992 | A |
5167633 | Mann et al. | Dec 1992 | A |
5167638 | Felix | Dec 1992 | A |
5171228 | McDonald | Dec 1992 | A |
5178612 | Fenton, Jr. | Jan 1993 | A |
5180365 | Ensminger et al. | Jan 1993 | A |
5185003 | Brethauer | Feb 1993 | A |
5201715 | Masters | Apr 1993 | A |
5203771 | Melker et al. | Apr 1993 | A |
5213574 | Fucker | May 1993 | A |
D337637 | Tucker | Jul 1993 | S |
5226879 | Ensminger et al. | Jul 1993 | A |
5263930 | Ensminger | Nov 1993 | A |
5266071 | Elftman | Nov 1993 | A |
5281199 | Ensminger et al. | Jan 1994 | A |
5281205 | McPherson | Jan 1994 | A |
5318545 | Tucker | Jun 1994 | A |
5336194 | Polaschegg et al. | Aug 1994 | A |
5350360 | Ensminger | Sep 1994 | A |
5360407 | Leonard et al. | Nov 1994 | A |
5387192 | Glantz et al. | Feb 1995 | A |
5395324 | Hinrichs et al. | Mar 1995 | A |
5399168 | Wadsworth, Jr. et al. | Mar 1995 | A |
5405325 | Labs | Apr 1995 | A |
5409463 | Thomas | Apr 1995 | A |
5417656 | Ensminger et al. | May 1995 | A |
5421814 | Geary | Jun 1995 | A |
5423334 | Jordan | Jun 1995 | A |
5476451 | Ensminger et al. | Dec 1995 | A |
5503630 | Ensminger et al. | Apr 1996 | A |
5514103 | Srisathapat et al. | May 1996 | A |
5520643 | Ensminger | May 1996 | A |
5527277 | Ensminger et al. | Jun 1996 | A |
5527278 | Ensminger et al. | Jun 1996 | A |
5531684 | Ensminger et al. | Jul 1996 | A |
5542923 | Ensminger et al. | Aug 1996 | A |
5554117 | Ensminger et al. | Sep 1996 | A |
5556381 | Ensminger et al. | Sep 1996 | A |
5558641 | Glantz et al. | Sep 1996 | A |
5562617 | Finch, Jr. et al. | Oct 1996 | A |
5562618 | Cai et al. | Oct 1996 | A |
5575770 | Melsky et al. | Nov 1996 | A |
5578070 | Utterberg | Nov 1996 | A |
5607393 | Ensminger et al. | Mar 1997 | A |
5613945 | Cai et al. | Mar 1997 | A |
5620419 | Lui | Apr 1997 | A |
5632729 | Cai et al. | May 1997 | A |
5647855 | Frooskin | Jul 1997 | A |
5695490 | Flaherty et al. | Dec 1997 | A |
5702363 | Flaherty | Dec 1997 | A |
5704915 | Melsky | Jan 1998 | A |
5713858 | Heruth et al. | Feb 1998 | A |
5718682 | Fucker | Feb 1998 | A |
5725507 | Petrick | Mar 1998 | A |
5741228 | Lambrecht | Apr 1998 | A |
5743873 | Cai et al. | Apr 1998 | A |
5758667 | Slettenmark | Jun 1998 | A |
5769823 | Otto | Jun 1998 | A |
5792104 | Speckman et al. | Aug 1998 | A |
5810789 | Powers et al. | Sep 1998 | A |
5833654 | Powers et al. | Nov 1998 | A |
5848989 | Villani | Dec 1998 | A |
5906596 | Tallarida | May 1999 | A |
5908414 | Otto et al. | Jun 1999 | A |
5913998 | Butler et al. | Jun 1999 | A |
5925017 | Kriesel et al. | Jul 1999 | A |
5931829 | Burbank et al. | Aug 1999 | A |
5944688 | Lois | Aug 1999 | A |
5947953 | Ash et al. | Sep 1999 | A |
5951512 | Dalton | Sep 1999 | A |
5954687 | Baudino | Sep 1999 | A |
5954691 | Prosl | Sep 1999 | A |
5968011 | Larsen et al. | Oct 1999 | A |
5989206 | Prosl et al. | Nov 1999 | A |
5989216 | Johnson et al. | Nov 1999 | A |
5989239 | Finch et al. | Nov 1999 | A |
6007516 | Burbank et al. | Dec 1999 | A |
6013051 | Nelson | Jan 2000 | A |
6013058 | Prosl et al. | Jan 2000 | A |
6022335 | Ramadan | Feb 2000 | A |
6039712 | Fogarty et al. | Mar 2000 | A |
6042569 | Finch, Jr. et al. | Mar 2000 | A |
6053901 | Finch, Jr. et al. | Apr 2000 | A |
6056717 | Finch et al. | May 2000 | A |
6086555 | Eliasen et al. | Jul 2000 | A |
6090067 | Carter | Jul 2000 | A |
6090068 | Chanut | Jul 2000 | A |
6102884 | Squitieri | Aug 2000 | A |
6120492 | Finch et al. | Sep 2000 | A |
6190349 | Ash et al. | Feb 2001 | B1 |
6190352 | Haarala et al. | Feb 2001 | B1 |
6206851 | Prosl | Mar 2001 | B1 |
6213973 | Eliasen et al. | Apr 2001 | B1 |
D445175 | Bertheas | Jul 2001 | S |
6287293 | Jones et al. | Sep 2001 | B1 |
6332874 | Eliasen et al. | Dec 2001 | B1 |
6350251 | Prosl et al. | Feb 2002 | B1 |
6352521 | Prosl | Mar 2002 | B1 |
6398764 | Finch, Jr. et al. | Jun 2002 | B1 |
6436084 | Finch et al. | Aug 2002 | B1 |
6438397 | Bosquet et al. | Aug 2002 | B1 |
6459917 | Gowda et al. | Oct 2002 | B1 |
6478783 | Moorehead | Nov 2002 | B1 |
6482197 | Finch et al. | Nov 2002 | B2 |
6494867 | Elver et al. | Dec 2002 | B1 |
6506182 | Estabrook et al. | Jan 2003 | B2 |
6527754 | Tallarida et al. | Mar 2003 | B1 |
6540717 | Sherry | Apr 2003 | B2 |
6582409 | Squitieri | Jun 2003 | B1 |
6607504 | Haarala et al. | Aug 2003 | B2 |
6620118 | Prosl et al. | Sep 2003 | B1 |
6695832 | Schon et al. | Feb 2004 | B2 |
6699218 | Flaherty et al. | Mar 2004 | B2 |
6719749 | Schweikert et al. | Apr 2004 | B1 |
6726711 | Langenbach et al. | Apr 2004 | B1 |
6758841 | Haarala et al. | Jul 2004 | B2 |
6783522 | Fischell | Aug 2004 | B2 |
6852106 | Watson et al. | Feb 2005 | B2 |
6881211 | Schweikert et al. | Apr 2005 | B2 |
6929631 | Brugger et al. | Aug 2005 | B1 |
6960185 | Adaniya et al. | Nov 2005 | B2 |
6962580 | Adams et al. | Nov 2005 | B2 |
6997914 | Smith et al. | Feb 2006 | B2 |
7018374 | Schon et al. | Mar 2006 | B2 |
7056316 | Burbank et al. | Jun 2006 | B1 |
7070591 | Adams et al. | Jul 2006 | B2 |
7083648 | Yu et al. | Aug 2006 | B2 |
7108686 | Burke et al. | Sep 2006 | B2 |
7131962 | Estabrook et al. | Nov 2006 | B1 |
7223257 | Shubayev et al. | May 2007 | B2 |
7261705 | Edoga et al. | Aug 2007 | B2 |
7311702 | Tallarida et al. | Dec 2007 | B2 |
7322953 | Redinger | Jan 2008 | B2 |
D562443 | Zinn et al. | Feb 2008 | S |
7347843 | Adams et al. | Mar 2008 | B2 |
7351233 | Parks | Apr 2008 | B2 |
7396359 | Derowe et al. | Jul 2008 | B1 |
D574950 | Zawacki et al. | Aug 2008 | S |
D578203 | Bizup | Oct 2008 | S |
7445614 | Bunodiere et al. | Nov 2008 | B2 |
D582032 | Bizup et al. | Dec 2008 | S |
7497850 | Halili | Mar 2009 | B2 |
D612479 | Zawacki et al. | Mar 2010 | S |
7699821 | Nowak | Apr 2010 | B2 |
7704225 | Kantrowitz | Apr 2010 | B2 |
7708722 | Glenn | May 2010 | B2 |
7713251 | Tallarida et al. | May 2010 | B2 |
7731680 | Patton | Jun 2010 | B2 |
7762999 | Byrum | Jul 2010 | B2 |
7824365 | Haarala et al. | Nov 2010 | B2 |
7846139 | Zinn et al. | Dec 2010 | B2 |
7850666 | Schon et al. | Dec 2010 | B2 |
7909804 | Stats | Mar 2011 | B2 |
7959615 | Stats et al. | Jun 2011 | B2 |
7972315 | Birk et al. | Jul 2011 | B2 |
7981094 | Chelak | Jul 2011 | B2 |
D650475 | Smith et al. | Dec 2011 | S |
8075536 | Gray et al. | Dec 2011 | B2 |
8079990 | Powley et al. | Dec 2011 | B2 |
8147455 | Butts et al. | Apr 2012 | B2 |
8152792 | Kornel | Apr 2012 | B1 |
8257325 | Schweikert et al. | Sep 2012 | B2 |
8277425 | Girard et al. | Oct 2012 | B2 |
8328768 | Quigley et al. | Dec 2012 | B2 |
8337464 | Young et al. | Dec 2012 | B2 |
8337465 | Young et al. | Dec 2012 | B2 |
8337470 | Prasad et al. | Dec 2012 | B2 |
8343108 | Rosenberg et al. | Jan 2013 | B2 |
8364230 | Simpson et al. | Jan 2013 | B2 |
8377034 | Tallarida et al. | Feb 2013 | B2 |
8425416 | Brister et al. | Apr 2013 | B2 |
8425476 | Glenn | Apr 2013 | B2 |
8480560 | Vendely | Jul 2013 | B2 |
8550981 | Woodruff et al. | Oct 2013 | B2 |
8574204 | Bourne et al. | Nov 2013 | B2 |
RE44639 | Squitieri | Dec 2013 | E |
8622980 | Zinn | Jan 2014 | B2 |
8690815 | Porter et al. | Apr 2014 | B2 |
8690816 | Dakin et al. | Apr 2014 | B2 |
8738151 | Nelson | May 2014 | B2 |
8979806 | Saab | Mar 2015 | B2 |
9033931 | Young et al. | May 2015 | B2 |
9061129 | Lauer | Jun 2015 | B2 |
9072880 | Phillips et al. | Jul 2015 | B2 |
9072881 | Dalton et al. | Jul 2015 | B2 |
9078982 | Lane et al. | Jul 2015 | B2 |
9089395 | Honaryar | Jul 2015 | B2 |
9095665 | Pages et al. | Aug 2015 | B2 |
9138563 | Glenn | Sep 2015 | B2 |
9168365 | Bourne et al. | Oct 2015 | B2 |
9174037 | Schutz et al. | Nov 2015 | B2 |
9179901 | Young et al. | Nov 2015 | B2 |
9180248 | Moberg et al. | Nov 2015 | B2 |
9474888 | Wiley et al. | Oct 2016 | B2 |
9579496 | Evans et al. | Feb 2017 | B2 |
9987467 | Jochum | Jun 2018 | B2 |
10207095 | Barron et al. | Feb 2019 | B2 |
10272236 | Davey | Apr 2019 | B2 |
10463845 | Stats et al. | Nov 2019 | B2 |
D870264 | Fedor et al. | Dec 2019 | S |
D885557 | Fedor et al. | May 2020 | S |
20010041870 | Gillis et al. | Nov 2001 | A1 |
20010056266 | Tallarida et al. | Dec 2001 | A1 |
20030023208 | Osypka et al. | Jan 2003 | A1 |
20030181878 | Tallarida et al. | Sep 2003 | A1 |
20040054352 | Adams et al. | Mar 2004 | A1 |
20040073196 | Adams et al. | Apr 2004 | A1 |
20040199129 | DiMatteo | Oct 2004 | A1 |
20040204692 | Eliasen | Oct 2004 | A1 |
20040254536 | Conlon et al. | Dec 2004 | A1 |
20040254537 | Conlon et al. | Dec 2004 | A1 |
20050075614 | Bunodiere et al. | Apr 2005 | A1 |
20050113806 | De Carvalho et al. | May 2005 | A1 |
20050131352 | Conlon et al. | Jun 2005 | A1 |
20050148956 | Conlon et al. | Jul 2005 | A1 |
20050148957 | Girard et al. | Jul 2005 | A1 |
20050171502 | Daly et al. | Aug 2005 | A1 |
20050203484 | Nowak | Sep 2005 | A1 |
20050209573 | Brugger et al. | Sep 2005 | A1 |
20050256451 | Adams et al. | Nov 2005 | A1 |
20050277899 | Conlon et al. | Dec 2005 | A1 |
20060084929 | Eliasen | Apr 2006 | A1 |
20060089619 | Ginggen | Apr 2006 | A1 |
20060100592 | Eliasen | May 2006 | A1 |
20060173424 | Conlon | Aug 2006 | A1 |
20060178617 | Adams et al. | Aug 2006 | A1 |
20060178647 | Stats | Aug 2006 | A1 |
20060184142 | Schon et al. | Aug 2006 | A1 |
20060217659 | Patton | Sep 2006 | A1 |
20060217673 | Schulze et al. | Sep 2006 | A1 |
20060224129 | Beasley et al. | Oct 2006 | A1 |
20060247584 | Sheetz et al. | Nov 2006 | A1 |
20060264898 | Beasley et al. | Nov 2006 | A1 |
20060271012 | Canaud et al. | Nov 2006 | A1 |
20070049806 | Adams et al. | Mar 2007 | A1 |
20070073250 | Schneiter | Mar 2007 | A1 |
20070078391 | Wortley et al. | Apr 2007 | A1 |
20070078416 | Eliasen | Apr 2007 | A1 |
20070083156 | Muto | Apr 2007 | A1 |
20070161958 | Glenn | Jul 2007 | A1 |
20070179456 | Glenn | Aug 2007 | A1 |
20070208313 | Conlon et al. | Sep 2007 | A1 |
20070219510 | Zinn et al. | Sep 2007 | A1 |
20070232997 | Glenn | Oct 2007 | A1 |
20070233017 | Zinn et al. | Oct 2007 | A1 |
20070233018 | Bizup et al. | Oct 2007 | A1 |
20070255234 | Haase et al. | Nov 2007 | A1 |
20070270770 | Bizup | Nov 2007 | A1 |
20070276344 | Bizup et al. | Nov 2007 | A1 |
20070282308 | Bell | Dec 2007 | A1 |
20080048855 | Berger | Feb 2008 | A1 |
20080086075 | Isik et al. | Apr 2008 | A1 |
20080108942 | Brister et al. | May 2008 | A1 |
20080114308 | di Palma et al. | May 2008 | A1 |
20080132946 | Mueller | Jun 2008 | A1 |
20080208236 | Hobbs et al. | Aug 2008 | A1 |
20080281279 | Hoendervoogt et al. | Nov 2008 | A1 |
20080319399 | Schweikert et al. | Dec 2008 | A1 |
20080319405 | Bizup | Dec 2008 | A1 |
20090024024 | Zinn | Jan 2009 | A1 |
20090024098 | Bizup | Jan 2009 | A1 |
20090099526 | Powley | Apr 2009 | A1 |
20090105688 | McIntyre | Apr 2009 | A1 |
20090118683 | Hanson | May 2009 | A1 |
20090156928 | Evans et al. | Jun 2009 | A1 |
20090192467 | Hansen et al. | Jul 2009 | A1 |
20090204074 | Powers et al. | Aug 2009 | A1 |
20090221976 | Linden | Sep 2009 | A1 |
20090259164 | Pages et al. | Oct 2009 | A1 |
20100042073 | Oster et al. | Feb 2010 | A1 |
20100121283 | Hamatake et al. | May 2010 | A1 |
20100298684 | Leach et al. | Nov 2010 | A1 |
20110118677 | Wiley et al. | May 2011 | A1 |
20110257577 | Lane et al. | Oct 2011 | A1 |
20110264058 | Linden et al. | Oct 2011 | A1 |
20110319728 | Petisce et al. | Dec 2011 | A1 |
20120172711 | Kerr et al. | Jul 2012 | A1 |
20120283518 | Hart | Nov 2012 | A1 |
20130030348 | Lauer | Jan 2013 | A1 |
20130150767 | Tsyrulnykov et al. | Jun 2013 | A1 |
20130150811 | Horgan | Jun 2013 | A1 |
20140207086 | Stats et al. | Jul 2014 | A1 |
20150190622 | Saab | Jul 2015 | A1 |
20150196704 | Adler | Jul 2015 | A1 |
20150250933 | Kerkhoffs et al. | Sep 2015 | A1 |
20150258322 | Young et al. | Sep 2015 | A1 |
20150265280 | Blatter et al. | Sep 2015 | A1 |
20150273201 | Tallarida et al. | Oct 2015 | A1 |
20150290446 | Wiley et al. | Oct 2015 | A1 |
20150306300 | Phillips et al. | Oct 2015 | A1 |
20150327844 | Hong et al. | Nov 2015 | A1 |
20160001055 | Bourne et al. | Jan 2016 | A1 |
20190232035 | Fedor et al. | Aug 2019 | A1 |
Number | Date | Country |
---|---|---|
1261698 | Sep 1989 | CA |
2318089 | Jul 1999 | CA |
2551680 | Jul 2005 | CA |
102271737 | Dec 2011 | CN |
0229729 | Jul 1987 | EP |
0366814 | May 1990 | EP |
0 809 523 | Dec 1997 | EP |
1047473 | Nov 2000 | EP |
1056506 | Dec 2000 | EP |
2948121 | Nov 2017 | EP |
H05-506591 | Sep 1993 | JP |
H07-148206 | Jun 1995 | JP |
H08-501008 | Feb 1996 | JP |
2008-531226 | Aug 2008 | JP |
1991012838 | Sep 1991 | WO |
1993005730 | Apr 1993 | WO |
1994005246 | Mar 1994 | WO |
9625196 | Aug 1996 | WO |
1996029112 | Sep 1996 | WO |
1997001370 | Jan 1997 | WO |
1997006845 | Feb 1997 | WO |
1998017337 | Apr 1998 | WO |
1999034859 | Jul 1999 | WO |
1999042166 | Aug 1999 | WO |
2000033901 | Jun 2000 | WO |
2000044424 | Aug 2000 | WO |
2000053245 | Sep 2000 | WO |
2001026713 | Apr 2001 | WO |
0180926 | Nov 2001 | WO |
2002038460 | May 2002 | WO |
2002066595 | Aug 2002 | WO |
2003066126 | Aug 2003 | WO |
2004004800 | Jan 2004 | WO |
2004071555 | Aug 2004 | WO |
2004091434 | Oct 2004 | WO |
2004093970 | Nov 2004 | WO |
2005068009 | Jul 2005 | WO |
2006064753 | Jun 2006 | WO |
2006078915 | Jul 2006 | WO |
2006096686 | Sep 2006 | WO |
2006116438 | Nov 2006 | WO |
2006130133 | Dec 2006 | WO |
2006134100 | Dec 2006 | WO |
2007079024 | Jul 2007 | WO |
2007082003 | Jul 2007 | WO |
2007087460 | Aug 2007 | WO |
2007092210 | Aug 2007 | WO |
2007094898 | Aug 2007 | WO |
2007098771 | Sep 2007 | WO |
2007109164 | Sep 2007 | WO |
2007126645 | Nov 2007 | WO |
2007136538 | Nov 2007 | WO |
2008048361 | Apr 2008 | WO |
2008063226 | May 2008 | WO |
2008140901 | Nov 2008 | WO |
2008157763 | Dec 2008 | WO |
2009002839 | Dec 2008 | WO |
2009012385 | Jan 2009 | WO |
2009035582 | Mar 2009 | WO |
2009046439 | Apr 2009 | WO |
2009108669 | Sep 2009 | WO |
2012064881 | May 2012 | WO |
2014017986 | Jan 2014 | WO |
2014116810 | Jul 2014 | WO |
2015179862 | Nov 2015 | WO |
2019200304 | Oct 2019 | WO |
Entry |
---|
“Merge”. Merriam-Webster Dictionary. https://www.merriam-webster.com/dictionary/merge. Access May 13, 2021. (Year: 2021). |
Canaud, B. et. al. “Dialock: a new vascular access device for extracorporeal renal replacement therapy. Preliminary clinical results”—Mar. 1999. |
CN 201480005902.2 filed Jul. 23, 2015 Office Action dated Jan. 20, 2016. |
CN 201480005902.2 filed Jul. 23, 2015 Office Action dated Jul. 19, 2016. |
CN 201480005902.2 filed Jul. 23, 2015 Office Action dated May 12, 2017. |
EP 14743846.9 filed Aug. 12, 2015 Extended European Search Report dated Oct. 10, 2016. |
EP 14743846.9 filed Aug. 12, 2015 Intent to Grant dated Jun. 26, 2017. |
Goldstein, D. J. et al. “Implantable Left Ventricular Assist Devices” (Nov. 19, 1998). |
Moran, J. E. “Subcutaneous Vascular Access Devices” (Nov. 1, 2001). |
PCT/US2014/012721 filed Jan. 23, 2014 International Search Report and Written Opinion dated Apr. 14, 2014. |
Rosenblatt, M. et. al. “Efficacy and Safety Results with the LifeSite Hemodialysis Access System versus the Tesio-Cath Hemodialysis Catheter at 12 Months”—Mar. 2006. |
Sandhu, J. Dialysis Ports: A New Totally Implantable Option for Hemodialysis Access—Jun. 2002. |
U.S. Appl. No. 14/162,113, filed Jan. 23, 2014 Final Office Action dated May 25, 2017. |
U.S. Appl. No. 14/162,113, filed Jan. 23, 2014 Non-Final Office Action dated May 4, 2016. |
U.S. Appl. No. 14/162,113, filed Jan. 23, 2014 Non-Final Office Action dated Nov. 22, 2016. |
JP 2015-555266 filed Jul. 22, 2015 Office Action dated May 2, 2018. |
JP 2015-555266 filed Jul. 22, 2015 Office Action dated Oct. 12, 2017. |
PCT/US2017/061179 filed Nov. 10, 2017 International Search Report and Written Opinion dated Jan. 22, 2018. |
U.S. Appl. No. 14/162,113, filed Jan. 23, 2014 Final Office Action dated Jul. 2, 2018. |
U.S. Appl. No. 14/162,113, filed Jan. 23, 2014 Non-Final Office Action dated Dec. 11, 2017. |
U.S. Appl. No. 14/162,113, filed Jan. 23, 2014 Notice of Allowance dated Aug. 14, 2019. |
U.S. Appl. No. 29/616,511, filed Sep. 6, 2017 Notice of Allowance dated Aug. 8, 2019. |
U.S. Appl. No. 29/716,554, filed Dec. 10, 2019 Notice of Allowance dated Feb. 6, 2020. |
Number | Date | Country | |
---|---|---|---|
20180078751 A1 | Mar 2018 | US |
Number | Date | Country | |
---|---|---|---|
62552681 | Aug 2017 | US | |
62421131 | Nov 2016 | US | |
61755913 | Jan 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14162113 | Jan 2014 | US |
Child | 15809879 | US |